Abstract Number: PB1072
Meeting: ISTH 2022 Congress
Background: Plasma exchange therapy (PET) with albumin replacement results in coagulation factors and platelets depletion. A close and timely monitoring of hemostasis is therefore warranted before PET, particularly in patients at risk of bleeding or those planned to receive large volume exchanges. The Quantra® system is a coagulation POC device based on Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry equipped with a disposable QPlus® 4-channel cartridge that performs 4 independent measurements with different combination of reagents. The output test results include Clot Time (CT), Clot Stiffness (CS), Fibrinogen Contribution to Clot Stiffness (FCS) and Platelet Contribution to Clot Stiffness (PCS).
Aims: To compare the Quantra® QPlus® parameters to routine laboratory parameters for near-POC monitoring of hemostasis in patients undergoing PET.
Methods: This prospective, single-center, observational study was conducted in the apheresis unit of a tertiary care center hospital from December 2021 to January 2022. Blood sampling was performed just before PET. SEER Sonorheometry was performed on a Quantra® analyzer with the QPlus® Cartridge (Stago BioCare, Asnières, France). Activated Partial Thromboplastin Time (aPTT) and functional fibrinogen level were determined on a STA-R Max analyzer using commercially available reagents (Stago, Asnières, France). Platelet count was performed on a XN 9100 analyzer using the Cellpack reagent (Sysmex, Villepinte, France). Statistical analysis was performed using GraphPad Prism version 8.4.2 (GraphPad Software, La Jolla California USA).
Results: 33 patients were prospectively enrolled in the study. Significant correlations were observed between CT and aPTT (r=0.62, p=0.001), FCS and fibrinogen levels (r=0.85, p < 0.0001), CS and fibrinogen levels (r=0.85, p < 0.0001), and PCS and platelet count (r=0.71, p < 0.0001). Result delivery was much faster with the Quantra® analyzer compared to conventional tests (mean time 35 versus 74 minutes, p < 0.0001).
Conclusion(s): SEER sonorheometry demonstrates significant correlations with routine laboratory tests and provided prompt information to manage hemostasis in patients undergoing PET.
To cite this abstract in AMA style:
Wahl C, Cornillot C, Maison M, Lhotellier L, Yangaju K, Dalibard M, Macraigne L, Lopez V, Chhing A, Frere C, Saheb S. Evaluation of the ultrasound sonorheometry based Quantra® System to monitor hemostasis in patients undergoing plasma exchange therapy [abstract]. https://abstracts.isth.org/abstract/evaluation-of-the-ultrasound-sonorheometry-based-quantra-system-to-monitor-hemostasis-in-patients-undergoing-plasma-exchange-therapy/. Accessed September 22, 2023.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-the-ultrasound-sonorheometry-based-quantra-system-to-monitor-hemostasis-in-patients-undergoing-plasma-exchange-therapy/